Specificities of SARS-CoV-2 infection in elderly patients
COVID-19 has strongly impacted the elderly population with a particularly high mortality rate due to several reasons: sometimes difficult and delayed diagnosis, multimorbidity, immunosenescence, frailty, which seems to be a better prognostic marker than age. Treatment includes both therapies specifically directed against SARS CoV-2 (monoclonal antibodies, systemic corticosteroids, tocilizumab, remdesivir) and symptomatic and palliative treatments. Vaccination, especially the booster, is essential to reduce the risk of infection and severe forms. The emergence of variants is a challenge because of their impact on vaccine and treatment efficacy. Specific studies in the elderly are needed to improve their management.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:18 |
|---|---|
| Enthalten in: |
Revue medicale suisse - 18(2022), 777 vom: 13. Apr., Seite 702-706 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Spécificités de l’infection à SARS-CoV-2 chez les patients âgés |
|---|
| Beteiligte Personen: |
Parent, Thibault [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 15.04.2022 Date Revised 15.04.2022 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.53738/REVMED.2022.18.777.702 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM339466227 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM339466227 | ||
| 003 | DE-627 | ||
| 005 | 20231226002947.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.53738/REVMED.2022.18.777.702 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1131.xml |
| 035 | |a (DE-627)NLM339466227 | ||
| 035 | |a (NLM)35417098 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Parent, Thibault |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Specificities of SARS-CoV-2 infection in elderly patients |
| 246 | 3 | 3 | |a Spécificités de l’infection à SARS-CoV-2 chez les patients âgés |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.04.2022 | ||
| 500 | |a Date Revised 15.04.2022 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a COVID-19 has strongly impacted the elderly population with a particularly high mortality rate due to several reasons: sometimes difficult and delayed diagnosis, multimorbidity, immunosenescence, frailty, which seems to be a better prognostic marker than age. Treatment includes both therapies specifically directed against SARS CoV-2 (monoclonal antibodies, systemic corticosteroids, tocilizumab, remdesivir) and symptomatic and palliative treatments. Vaccination, especially the booster, is essential to reduce the risk of infection and severe forms. The emergence of variants is a challenge because of their impact on vaccine and treatment efficacy. Specific studies in the elderly are needed to improve their management | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 700 | 1 | |a Skoula, Eirini |e verfasserin |4 aut | |
| 700 | 1 | |a Vetter, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Prendki, Virginie |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Revue medicale suisse |d 2005 |g 18(2022), 777 vom: 13. Apr., Seite 702-706 |w (DE-627)NLM154244252 |x 1660-9379 |7 nnns |
| 773 | 1 | 8 | |g volume:18 |g year:2022 |g number:777 |g day:13 |g month:04 |g pages:702-706 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.53738/REVMED.2022.18.777.702 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 18 |j 2022 |e 777 |b 13 |c 04 |h 702-706 | ||